Tyra Biosciences (TYRA) director awarded 13,160 stock options at $32.68 strike

Rhea-AI Filing Summary

Tyra Biosciences director Rehan Verjee received a stock option grant covering 13,160 shares of common stock, with an exercise price of $32.68 per share. The option was granted under the Non-Employee Director Compensation Program and vests in 12 equal monthly installments after May 28, 2026, with any remaining unvested portion vesting at the next annual stockholder meeting if it occurs within a year and service continues. Following this award, Verjee holds options for 13,160 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Verjee Rehan

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	13,160	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 13,160 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 13,160 shares Exercise price: $32.68 per share Post-grant option holdings: 13,160 shares +2 more

5 metrics

Option grant size 13,160 shares Stock Option (Right to Buy) granted May 28, 2026

Exercise price $32.68 per share Conversion or exercise price for granted options

Post-grant option holdings 13,160 shares Total derivative securities following transaction

Option expiration date May 27, 2036 Expiration date of the stock option grant

Monthly vesting fraction 1/12 per month Vesting schedule after May 28, 2026

Key Terms

Non-Employee Director Compensation Program, stock option, vesting, expiration date

4 terms

Non-Employee Director Compensation Program financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

stock option financial

"The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vesting financial

"1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date": "2036-05-27T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verjee Rehan

(Last) (First) (Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD CALIFORNIA 92008

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.68	05/28/2026		A		13,160		(1)	05/27/2036	Common Stock	13,160	$0	13,160	D

Explanation of Responses:

1. The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Ali D. Fawaz, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tyra Biosciences (TYRA) director Rehan Verjee report on this Form 4?

Rehan Verjee reported receiving a stock option grant for 13,160 shares of Tyra Biosciences common stock. The option was awarded as part of the company’s Non-Employee Director Compensation Program, reflecting routine equity-based compensation for board service rather than an open-market stock purchase or sale.

How many Tyra Biosciences (TYRA) shares are covered by the new stock option grant?

The stock option grant covers 13,160 shares of Tyra Biosciences common stock. These options give the director the right to buy shares at a fixed exercise price in the future, subject to the vesting schedule and continued service conditions described in the Form 4 footnote.

What is the exercise price of the new Tyra Biosciences (TYRA) stock options?

The exercise price of the new stock options is $32.68 per share. This means the director can purchase Tyra Biosciences common stock at $32.68 once the options vest, regardless of the market price at that time, provided all vesting and service conditions are met.

How do the Tyra Biosciences (TYRA) director’s options vest under this grant?

One-twelfth of the 13,160-share option vests monthly after May 28, 2026, the grant date. If the next annual stockholder meeting occurs before the first anniversary of the grant, any remaining unvested options vest at that meeting, assuming continuous service through each vesting date.

When do the newly granted Tyra Biosciences (TYRA) stock options expire?

The newly granted stock options expire on May 27, 2036. After this expiration date, any unexercised portion of the option will lapse and can no longer be used to purchase Tyra Biosciences common shares, even if previously vested under the compensation program.

Is this Tyra Biosciences (TYRA) Form 4 a market purchase or sale of shares?

This Form 4 reports a grant of stock options, not a market purchase or sale of common shares. The options were issued at no cost under the Non-Employee Director Compensation Program and represent compensation, with potential future share acquisitions if the director exercises vested options.